Table 1 (abstract P120). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | n | Female (%) | Age at first IL-1 inhibitor started (years), median (Q1-Q3) | Age at onset (years), median (Q1-Q3) | Age at diagnosis (years), median (Q1-Q3) |
|---|---|---|---|---|---|
FMF | 11 | 2 (18,18) | 15,06 (11,16-17,60) | 4,00 (1,75-6,77) | 6,70 (4,35-11,61) |
HIDS | 9 | 4 (44,44) | 7,85 (6,17-13,16) | 4 (1,75-6,77) | 6,38 (5-12) |
TRAPS | 6 | 1 (16,66) | 10,46 (4,60-13,47) | 4,50 (2,44-6,63) | 8,01 (2,57-9,00) |
CAPS | 2 | 0 | 4,92 | 2,08 | 4,60 |
PAPA | 2 | 0 | 9,60 | 5 | 9,47 |
APLAID | 1 | 0 | 4,17 | 2,5 | 3,74 |
All | 31 | 7 (22,58) | 11,01 (6,71-14,45) | 3,00 (1,33-5,50) | 6,97 (4,13-11,23) |